|
Progress:
Bryostatin (Bryo), a macrolide lactone with efficacy in subnanomolar concentrations and a potential therapeutic for Alzheimer's disease, is a potent activator of PKC, some of whose isozymes undergo prolonged activation after associative learning. Under normal conditions, two training events with paired visual and vestibular stimuli cause short-term memory in the mollusc Hermissenda that lasts about 7 min. However, after four-hour exposures to Bryo (0.25ng/ml), on two preceding days, the same 2 training events produced long-term conditioning that lasted more than 1 week and that was not blocked by anisomycin (1µg/ml). Anisomycin, however, eliminated LTM lasting at least one week after 9 training events. Both the 9 training events and Bryo (x2)+2 training event regimens caused comparably increased levels of the PKC -isozyme substrate calexcitin in identified Type B neurons and enhanced PKC activity in both cytosol and membrane fractions. Furthermore, Bryo increased overall protein synthesis in cultured mammalian neurons by up to 60% for more than 3 days. The specific PKC antagonist, Ro-32-0432, blocked much of this Bryo-induced protein synthesis as well as the Bryo-induced enhancement of the behavioral conditioning. Thus, Bryo-induced PKC activation produces those proteins necessary and sufficient required for long-term memory on days in advance of the training events themselves.
|